Potential risks of eliciting antibodies enhancing HIV-1 infection of monocytic cells by vaccination with V3 loops of unmatched HIV-1 isolates.
Jiang
S
S
Neurath
A R
AR
D016915:AIDS Vaccines / Q000009:adverse effects*; D015483:HIV Antibodies / Q000009:adverse effects*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology; D015497:HIV-1 / Q000276:immunology* / Q000502:physiology; D006801:Humans; D008264:Macrophages / Q000276:immunology / Q000382:microbiology; D009000:Monocytes / Q000276:immunology / Q000382:microbiology; D010446:Peptide Fragments / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000009:adverse effects*
D016915:AIDS Vaccines; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D014614:Vaccines, Synthetic